What Liquid Cartilage™ actually needs from your hip joint

Not every hip cartilage problem is the same shape — and the shape matters enormously when it comes to Liquid Cartilage™.

Developed by Professor Paul Lee, Liquid Cartilage™ uses ChondroFiller™, a CE-marked Class III collagen scaffold, placed into a focal cartilage defect in the hip joint. The scaffold gels in situ within minutes of placement and works through acellular matrix-induced chondrogenesis: it creates a structured environment that recruits the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — which then mature into chondrocyte-like cells and support the body's own repair processes at that defined site. The scaffold is gradually resorbed as repair progresses over six to twelve months.

That mechanism carries a specific dependency. For progenitor cells to migrate into the scaffold in meaningful numbers, the tissue bordering the defect must be reasonably intact. A focal, contained lesion — one with clear boundaries and viable cartilage at its margins — supplies that cellular reservoir. The procedure is therefore designed around a target: a bounded area of Grade III or Grade IV damage, up to approximately 6 cm², set within a joint that is otherwise structurally sound.

MRI assessment of the hip is the essential gateway before any pathway decision at Lincolnshire Hip. Imaging establishes the defect's pattern (focal or diffuse), depth, area, and the health of the surrounding cartilage and subchondral bone. It also reveals mechanical factors — such as femoroacetabular impingement or joint alignment — that could undermine any regenerative attempt before it begins.

When those conditions are not met, the scaffold has no viable site to work within. Understanding why leads directly to understanding who falls outside Liquid Cartilage™'s range.

Hip conditions that put Liquid Cartilage™ out of reach

The focal-versus-diffuse distinction is the central concept. When hip wear is widespread — coating multiple surfaces rather than concentrated at a single bounded site — there is simply no defined target for the scaffold to occupy. Liquid Cartilage™ depends on excavating and filling a contained defect; diffuse cartilage loss across the hip joint surface offers neither a margin to build from nor a meaningful boundary to work within.

Advanced osteoarthritis makes this concrete. Kellgren–Lawrence Grade IV disease — characterised by bone-on-bone contact within the hip joint — is an explicit hard exclusion. At that stage, no viable surface remains to anchor or border a scaffold, and the cellular environment required for matrix-induced chondrogenesis cannot function. This is not a borderline call: there is no variant of Liquid Cartilage™ that addresses end-stage OA of the hip.

Defect characteristics matter beyond pattern alone. Lesions extending through the subchondral bone (Grade IV depth) mark the boundary of surface regeneration approaches — repair biology depends on a functioning subchondral plate beneath the scaffold. Where the surrounding cartilage is itself significantly degenerate rather than reasonably preserved, the progenitor cell supply that drives repair is compromised. Such cases may still reach consultation, but are frequently redirected to a different pathway.

These thresholds guide rather than dictate the final decision. Two patients with similar pain levels may sit on opposite sides of the threshold when their imaging is compared; that is why the defect pattern, depth, area, and surrounding tissue quality on MRI lead the assessment — not the severity of symptoms alone.

Mechanical barriers — FAI, instability, and joint environment

Resolving a mechanical problem — FAI in particular — can shift a patient from unsuitable to suitable for cartilage repair, which is a key reason the whole-joint assessment matters.

Femoroacetabular impingement arises when an abnormal bone shape at the hip creates repetitive contact that abrades the cartilage surface. Left untreated, it places any regenerating scaffold under the same abnormal load that caused the original damage, preventing the repair process from consolidating. Where FAI is identified and correctable — addressed alongside or before any cartilage procedure — treatment of the impingement itself may open candidacy rather than close it.

Ligament laxity and significant hip instability introduce a different mechanical problem: shear forces across the joint surface that a maturing scaffold cannot withstand. Significant malalignment alters where load concentrates across the hip, redistributing stress away from where repair is expected to occur. Both create a hostile environment that undermines the biology of regeneration, irrespective of how well the scaffold is placed.

These mechanical prerequisites are not exclusive to Liquid Cartilage™. Any cartilage repair approach — including the ChondroFiller® injection — requires a joint environment stable enough to allow repair processes to work. A scaffold in a mechanically compromised hip faces the same challenge regardless of technique.

Professor Paul Lee's assessment at Lincolnshire Hip evaluates the whole joint, not only the focal defect. Clinical examination, imaging, and gait analysis together establish whether the mechanical environment supports repair — and whether correcting a structural issue first would change what is on the table.

ChondroFiller® injection — the joint-preservation step for wider hip wear

The ChondroFiller® injection is distinct from Liquid Cartilage™ in a way that matters practically: where the surgical procedure targets a contained focal defect, the injection delivers the same collagen scaffold across the entire articular surface of the hip joint in a single ultrasound-guided outpatient appointment.

That difference in delivery has direct consequences for candidacy. Because the scaffold coats the whole joint rather than filling a discrete excavated site, there is no defect-size ceiling and no upper age limit. Patients with more diffuse hip wear — the pattern that disqualifies them from the surgical pathway — can be considered for the injection. So can those in their 60s, 70s, and beyond who want to attempt joint preservation before replacement but for whom the regenerative demands and physical burden of keyhole surgery are less appropriate.

The mechanism is the same as in the surgical route — the collagen scaffold recruits the patient's own progenitor cells to support the repair process — but it operates across a broader surface area without arthroscopic delivery, theatre time, or surgical wound recovery. At Lincolnshire Hip, this is an in-clinic procedure carried out by Professor Lee under ultrasound guidance in Grantham or Sleaford. A guide cost of £2,995 covers the collagen scaffold dose, the ultrasound-guided injection, and a local follow-up appointment; the exact figure is confirmed at consultation.

The injection is not a like-for-like substitute for the surgical pathway in every respect. For a well-defined focal defect in a patient whose biology supports full regeneration, Liquid Cartilage™ may still offer more targeted repair. The injection's value lies precisely in its breadth — it extends the preservation option to a wider group of hip patients, including those for whom arthroscopy is not the right next step.

Other pathways between injection and replacement — NanoACi™, PRP, HA, and Arthrosamid

The options between a ChondroFiller® injection and hip replacement are not a generic cluster — each operates through a different mechanism and tends to suit a different clinical picture.

NanoACi™ sits closest to Liquid Cartilage™ in biological ambition: Professor Lee's one-stage technique combines autologous cartilage micrografts, a cell-free collagen matrix, and autologous PRF, all prepared at point of care and delivered by needle rather than arthroscope. It is more biologically intensive than the ChondroFiller® injection alone but avoids the physical burden of keyhole surgery — a meaningful distinction for patients for whom arthroscopy is not appropriate but injection alone may be insufficient. Published hip-specific data remain limited, so suitability is decided at consultation from imaging rather than symptoms.

PRP supports the joint's own repair environment rather than rebuilding cartilage directly. It tends to be considered earlier in the pathway — when wear is less advanced and the aim is to support the hip's biology — though preparation method affects what the injection delivers, a detail worth raising at consultation.

Hyaluronic acid is a symptom-management option, not a regenerative one. It improves joint lubrication and may reduce mechanical discomfort, but does not address the underlying cartilage deficit and should not be framed as a repair strategy.

Arthrosamid is a permanent polyacrylamide hydrogel — a cushioning agent, not a scaffold or biologic. It is not regenerative and works through a different mechanism from ChondroFiller®; it tends to be considered where mechanical cushioning of the joint space is the primary clinical need rather than tissue repair.

The appropriate choice across all these options depends on imaging findings, age, activity level, and individual goals — assessed at Lincolnshire Hip consultation.

When hip replacement becomes the logical next step

For some hip patients, every preservation pathway eventually reaches its limit. When MRI and clinical assessment confirm bone-on-bone contact throughout the joint and no injection or scaffold procedure is viable, hip replacement is not a last resort — it is the appropriate and well-supported next step, and reaching it through a structured clinical process is very different from arriving there unexpectedly.

At Lincolnshire Hip, the surgical option relevant to this point in the pathway is the SPAIRE technique — a minimally invasive approach that preserves the key muscles and tendons around the hip rather than dividing them, reducing soft-tissue trauma and supporting a faster return to ordinary activity compared with conventional approaches.

Crucially, patients do not need to restart their journey at this stage. The move from cartilage preservation assessment to replacement discussion happens within the same clinical structure, with the same consultant who has reviewed the imaging and considered the non-surgical options. That continuity matters when the decision itself is significant.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral — the pathway, from first assessment to whichever step proves right, begins at a single point of contact.